Pharmaceutical Water System — From Bore Well to Purified Water

 

Water is a critical utility in pharmaceutical manufacturing—and its quality directly impacts product quality, process control, cleaning, and patient safety.

This infographic presents the typical pharmaceutical water treatment pathway, from bore-well raw water to Purified Water, covering key stages such as:

🔹 Raw Water Storage
🔹 Multimedia Filtration
🔹 Activated Carbon Filtration
🔹 Water Softening
🔹 Micron Filtration
🔹 Reverse Osmosis (RO)
🔹 UV Disinfection
🔹 Polishing / EDI
🔹 Purified Water Storage & Distribution Loop
🔹 Point-of-Use Filtration

A robust pharmaceutical water system should be appropriately designed, qualified, validated, monitored, maintained, and documented in accordance with applicable regulatory and GMP expectations, including USFDA, ICH Q7 and Schedule M, as applicable.

💧 Ensure Purity. Ensure Compliance. Ensure Patient Safety.

📚 Explore more pharmaceutical knowledge at:
🌐 www.pharmatext.co.in

#PharmaceuticalWaterSystem #PurifiedWater #WaterPurification #PharmaWater #USFDA #ICH #ScheduleM #GMP #PharmaceuticalManufacturing #PharmaEngineering #WaterTreatment #ROSystem #EDI #Validation #Qualification #GMPCompliance #PharmaceuticalIndustry #PharmaProfessionals #Pharmatext #DrugManufacturing

GDUFA IV: What’s Changing for ANDA Stakeholders?

The FDA’s draft GDUFA IV Commitment Letter proposes several important enhancements to the generic drug review program for FY2028–FY2032.

Key changes include shorter priority review goals, stronger pre-submission facility correspondence (PFC), Discipline Review Letters (DRLs), improved DMF–ANDA coordination, standardized data requirements, enhanced inspection pathways, and greater performance & financial transparency.

🎯 The overarching objective: fewer review cycles, faster timelines, greater predictability, and stronger early engagement between FDA and generic drug applicants.

This poster provides a quick comparison of GDUFA III vs. the proposed GDUFA IV commitments for regulatory affairs, generic drug manufacturers, and ANDA stakeholders.

📌 Follow Pharmatext for pharma regulatory updates, FDA developments, and industry insights.

🌐 www.pharmatext.co.in

hashtag#GDUFAIV hashtag#GDUFA hashtag#FDA hashtag#USFDA hashtag#ANDA hashtag#GenericDrugs hashtag#PharmaceuticalIndustry hashtag#PharmaRegulatory hashtag#RegulatoryAffairs hashtag#FDAUpdates hashtag#GenericDrugDevelopment hashtag#DMF hashtag#ANDAReview hashtag#PharmaceuticalRegulations hashtag#DrugRegulatory hashtag#PharmaUpdates hashtag#USFDAUpdates hashtag#PharmaIndustry hashtag#Pharmatext hashtag#PharmaRegulatoryAffairs

GxP System vs Non-GxP System — Why Does It Matter?

In the pharmaceutical industry, a computerized system is not simply an IT tool—it can directly impact product quality, data integrity, regulatory compliance, and ultimately patient safety.

Our latest comparison highlights the key differences between GxP and Non-GxP systems, including:

🔹 Regulatory Compliance
🔹 Data Integrity & ALCOA+ Principles
🔹 Documentation & Record Keeping
🔹 Quality Assurance
🔹 Risk Management
🔹 Change Control
🔹 Audit & Inspection Readiness
🔹 Training & Competency
🔹 Patient Safety
🔹 Business & Regulatory Impact
A properly designed, validated and controlled GxP system provides confidence that critical data remains accurate, reliable, traceable and compliant throughout its lifecycle.
📌 Know your system. Assess its GxP impact. Protect your data.

🌐 www.pharmatext.co.in
Your Partner in Regulatory Compliance & Quality Excellence

hashtag#GxP hashtag#GxPCompliance hashtag#ComputerizedSystemValidation hashtag#CSV hashtag#DataIntegrity hashtag#ALCOAPlus hashtag#PharmaceuticalIndustry hashtag#PharmaCompliance hashtag#QualityAssurance hashtag#RegulatoryCompliance hashtag#21CFRPart11 hashtag#GMP hashtag#FDA hashtag#PharmaQA hashtag#Validation hashtag#DataIntegrityInPharma hashtag#PatientSafety hashtag#PharmaTech hashtag#Pharmatext